{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:22:54Z","timestamp":1768645374104,"version":"3.49.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.2217\/fon-2020-1088","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T09:34:16Z","timestamp":1611308056000},"page":"1581-1591","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Elotuzumab in the Treatment of Relapsed and Refractory Multiple Myeloma"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-1050","authenticated-orcid":false,"given":"Sebastian","family":"Grosicki","sequence":"first","affiliation":[{"name":"Department of Hematology & Cancer Prevention, \rChorzow, Faculty of Health Sciences, \rBytom, Medical University of Silesia, \r40-055 \rKatowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyna","family":"Bednarczyk","sequence":"additional","affiliation":[{"name":"Department of Hematology & Cancer Prevention, \rChorzow, Faculty of Health Sciences, \rBytom, Medical University of Silesia, \r40-055 \rKatowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Barchnicka","sequence":"additional","affiliation":[{"name":"Clinical Department of Hematology & Cancer Prevention,Municipal Hospital, \r41-500 \rChorzow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Grosicka","sequence":"additional","affiliation":[{"name":"Institute of Economics,Finance & Management,Faculty of Management & Social Communication,Jagiellonian University, \r31-007 \rCracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.04.003"},{"issue":"4","key":"e_1_3_2_8_1","first-page":"15","article-title":"Profile of elotuzumab and its potential in the treatment of multiple myeloma","volume":"2014","author":"Liu YC","year":"2014","unstructured":"LiuYC, SzmaniaS, van RheeF. Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood Lymphat. Cancer 2014(4), 15\u201327 (2014).","journal-title":"Blood Lymphat. Cancer"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.achaem.2015.11.003"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1693"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-183772"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1279603"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02551"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339853"},{"issue":"5","key":"e_1_3_2_17_1","first-page":"542","article-title":"Elotuzumab the first monoclonal antibody for the treatment of multiple myeloma","volume":"7","author":"Fancher K","year":"2016","unstructured":"FancherK, BunkE. Elotuzumab the first monoclonal antibody for the treatment of multiple myeloma. J. Adv. Pract. Oncol. 7(5), 542\u2013547 (2016).","journal-title":"J. Adv. Pract. Oncol."},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S117477"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0585-6"},{"key":"e_1_3_2_20_1","unstructured":"NIH. Japanese study of (BMS-901608) (elo-tuzumab) in combination with lenalidomide and low dose dexamethasone. (2015). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01241292"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"BerdejaJ JagannathS ZonderJet al.Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a Phase Ib study. 16(3) 129\u2013138 (2016).","DOI":"10.1016\/j.clml.2015.12.007"},{"key":"e_1_3_2_22_1","unstructured":"NIH. Biomarker study of elotuzumab in high risk smoldering myeloma. (2015). www.clinicaltrials.gov\/ct2\/show\/NCT01441973"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-0033-9"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160554"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.676175"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7069"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2138-4"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00197-0"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694604"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14263"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14787"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31680"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00357-4"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1685879"},{"key":"e_1_3_2_38_1","unstructured":"Empliciti. Empliciti US product information. Bristol Myers Squibb NJ USA (2018)."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/196063"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.03.011"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0285"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1199947"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-546374"},{"key":"e_1_3_2_47_1","first-page":"S2152","article-title":"Expression of the immune checkpoint regulators LAG-3 and TIM-3 in classical Hodgkin lymphoma","volume":"12","author":"El Halabi L","year":"2020","unstructured":"ElHalabi L, AdamJ, GravellePet al.Expression of the immune checkpoint regulators LAG-3 and TIM-3 in classical Hodgkin lymphoma. Clin. Lymphoma Myeloma Leuk. 12, S2152\u2013S2650 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825265"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15384"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:57Z","timestamp":1719125217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.2217\/fon-2020-1088"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1088","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}